
CureVac N.V. CVAC
Quarterly report 2022-Q2
added 08-18-2022
CureVac N.V. Gross Profit 2011-2026 | CVAC
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit CureVac N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -10.6 M | -4.87 M | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.87 M | -10.6 M | -7.72 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
AbbVie
ABBV
|
12.1 B | $ 208.84 | -2.86 % | $ 369 B | ||
|
Grifols, S.A.
GRFS
|
2.79 B | $ 8.24 | -0.12 % | $ 6.83 B | ||
|
Ascendis Pharma A/S
ASND
|
625 M | $ 229.25 | 0.44 % | $ 5 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B | ||
|
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
ANI Pharmaceuticals
ANIP
|
143 M | $ 74.21 | -2.3 % | $ 1.43 B | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
Cocrystal Pharma
COCP
|
7.22 M | $ 1.51 | 48.04 % | $ 17 M | ||
|
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
BioMarin Pharmaceutical
BMRN
|
1.34 B | $ 55.5 | -3.04 % | $ 10.6 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
9.54 M | $ 8.03 | 2.29 % | $ 220 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
62.8 M | $ 14.81 | 2.63 % | $ 2.25 B | ||
|
Altimmune
ALT
|
8.18 K | $ 3.34 | 7.05 % | $ 294 M | ||
|
Amgen
AMGN
|
19 B | $ 347.94 | -1.51 % | $ 187 B | ||
|
Aurinia Pharmaceuticals
AUPH
|
-52.5 M | $ 15.61 | 0.9 % | $ 2.1 B | ||
|
Bristol-Myers Squibb Company
BMY
|
18.1 B | $ 59.6 | -2.45 % | $ 121 B | ||
|
Aptinyx
APTX
|
1.56 K | - | -39.0 % | $ 4.57 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
44.7 M | $ 9.02 | -3.84 % | $ 1.86 B | ||
|
BeiGene, Ltd.
BGNE
|
4.67 B | - | 0.49 % | $ 251 B | ||
|
Cellectis S.A.
CLLS
|
37.7 M | $ 3.41 | 1.19 % | $ 116 M | ||
|
Biogen
BIIB
|
12.4 B | $ 177.34 | -3.5 % | $ 26 B | ||
|
Axon Enterprise
AXON
|
1.24 B | $ 412.81 | -2.54 % | $ 31.3 B |